Why the study?
Does combined steroid and cyclophosphamide treatment improve myocardial contraction as measured by ultrasonic tissue characterization in a patient with SLE and acute myocarditis?
Does combined steroid and cyclophosphamide treatment improve myocardial contraction as measured by ultrasonic tissue characterization in a patient with SLE and acute myocarditis?
Ultrasonic tissue characterization using integrated backscatter may be a useful method to evaluate myocardial contraction and monitor the clinical course of myocardial involvement in systemic lupus erythematosus.
Answers are grounded in this paper and cite their sources.
Single-case improvement in integrated backscatter after immunosuppression in SLE myocarditis; leaves open its reliability for monitoring myocardial recovery.
Although myocarditis from a series of autopsies of patients with systemic lupus erythematosus was frequently observed, the incidence of clinically apparent myocardial dysfunction was low. A 30-year-old woman with systemic lupus erythematosus was examined by echocardiography. An acoustic densitometry was followed at the left ventricular posterior wall throughout the clinical course. A decrease in the magnitude of cyclic variation of integrated backscatter (IB) was observed before treatment. Following the combined treatment, steroid and cyclophosphamide, a repeated ultrasonic tissue characterization showed an increase in the magnitude of cyclic variation of IB. It is thought that ultrasonic tissue characterization may be a useful method to evaluate the impairment of contraction, and to follow up the clinical course of myocardial involvement in systemic lupus erythematosus.
No takes yet. Share an insight, caveat, or question.
Ueda et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: